{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:14:29Z","timestamp":1792134869525,"version":"4.4.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07555-x","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:25:10Z","timestamp":1758536710000},"page":"2047-2053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2862-010X","authenticated-orcid":false,"given":"Caroline","family":"Boursier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Zaragori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Garabedian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Blonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Taillandier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Imbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Verger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"7555_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae069","author":"MJ Mair","year":"2024","unstructured":"Mair MJ, Tabouret E, Johnson DR, Sulman EP, Wen PY, Preusser M, Albert NL. Radioligand therapies in meningioma: evidence and future directions. Neuro-Oncol. 2024. https:\/\/doi.org\/10.1093\/neuonc\/noae069.","journal-title":"Neuro-Oncol"},{"key":"7555_CR2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.249607","author":"C Mirian","year":"2021","unstructured":"Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, et al. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: individual patient data meta-analysis. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.249607.","journal-title":"J Nucl Med"},{"key":"7555_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not330","author":"T Kaley","year":"2014","unstructured":"Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncol. 2014. https:\/\/doi.org\/10.1093\/neuonc\/not330.","journal-title":"Neuro-Oncol"},{"key":"7555_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now060","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Stoecklein V, Sch\u00fcller U, Rushing E, Nicolas G, Sch\u00e4fer N, Ilhan H, Pangalu A, Weller M, Tonn J-C, Sommerauer M, Albert NL. Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68 Ga-DOTATATE\/-TOC uptake. Neuro-Oncol. 2016. https:\/\/doi.org\/10.1093\/neuonc\/now060.","journal-title":"Neuro-Oncol"},{"key":"7555_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06044-9","author":"NS Minczeles","year":"2023","unstructured":"Minczeles NS, Bos EM, De Leeuw RC, Kros JM, Konijnenberg MW, Bromberg JEC, De Herder WW, Dirven CMF, Hofland J, Brabander T. Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-022-06044-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7555_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07336-6","author":"N Hasenauer","year":"2025","unstructured":"Hasenauer N, M\u00fcller M, H\u00e4nscheid H, Serfling SE, Michalski K, Heinrich M, et al. Sstr-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07336-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7555_CR7","doi-asserted-by":"publisher","DOI":"10.23736\/S1824-4785.24.03571-4","author":"C Boursier","year":"2024","unstructured":"Boursier C, Zaragori T, Imbert L, Verger A. 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review. Q J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.23736\/S1824-4785.24.03571-4.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"7555_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06783-x","author":"NL Albert","year":"2024","unstructured":"Albert NL, Preusser M, Traub-Weidinger T, Tolboom N, Law I, Palmer JD, Guedj E, Furtner J, Fraioli F, Huang RY, Johnson DR, Deroose CM, Herrmann K, Vogelbaum M, Chang S, Tonn J-C, Weller M, Wen PY, Van Den Bent MJ, Verger A, Ivanidze J, Galldiks N, Joint. Diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06783-x. EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7555_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy137","author":"RY Huang","year":"2019","unstructured":"Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro-Oncol. 2019. https:\/\/doi.org\/10.1093\/neuonc\/noy137.","journal-title":"Neuro-Oncol"},{"key":"7555_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04622-5","author":"T Graillon","year":"2024","unstructured":"Graillon T, Salgues B, Horowitz T, Padovani L, Appay R, Tabouret E, Guedj E, Chinot O. Peptide radionuclide radiation therapy with lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis. J Neurooncol. 2024. https:\/\/doi.org\/10.1007\/s11060-024-04622-5.","journal-title":"J Neurooncol"},{"key":"7555_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09697-8","author":"C Boursier","year":"2023","unstructured":"Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, Blonski M, Roch V, Marie P-Y, Karcher G, Imbert L, Verger A. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy. Eur Radiol. 2023. https:\/\/doi.org\/10.1007\/s00330-023-09697-8.","journal-title":"Eur Radiol"},{"key":"7555_CR12","doi-asserted-by":"publisher","unstructured":"Sommerauer M, Burkhardt J-K, Frontzek K, Rushing E, Buck A, Krayenbuehl N, Weller M, Schaefer N, Kuhn FP. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? Neuro-Oncol. 2016; https:\/\/doi.org\/10.1093\/neuonc\/now001","DOI":"10.1093\/neuonc\/now001"},{"key":"7555_CR13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267023","author":"K Hebert","year":"2024","unstructured":"Hebert K, Santoro L, Monnier M, Castan F, Berkane I, Ass\u00e9nat E, et al. Absorbed dose\u2013response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [177 Lu]Lu-DOTATATE: one step closer to personalized medicine. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.123.267023.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07555-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:01Z","timestamp":1769834581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07555-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7555"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07555-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study (Clinical Trials NCT06614205) was approved by the ethics committee of the Regional University Hospital of Nancy (no. 457, September 11, 2024) and the requirement to obtain informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors disclose no potential conflicts of interest related to the present work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}}]}}